Nimblify’s Participant Payment System Makes Its Debut
Participant Payments provides clinical research sites the choice to pay participants via reloadable debit card, direct deposit or check.
Nimblify, Inc., a clinical trials technology company and wholly owned subsidiary of Forte Research Systems, has launched its first offering, a participant-centered payment system. Participant Payments provides clinical research sites the choice to pay participants via reloadable debit card, direct deposit or check, without additional work for the site. In addition to an improved patient experience, Participant Payments provides coordinators the ability to set clear expectations with participants with the help of protocol-specific guidelines, including pre-approved stipend amounts and maximums for hotel and parking reimbursements.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
